Biogen believes that some of its new drugs, Leqembi, Skyclarys and Zurzuvae, have the potential to revive long-term growth. Can Biogen achieve this goal?

The European Union's medicines regulator on Friday reiterated its positive recommendation for Eisai and Biogen's Alzheimer's ...

Sage Therapeutics (NASDAQ:SAGE) stock drops as Bank of America issues an Underperform rating citing an end to Biogen's (BIIB) ...

Days after suffering a rejection in Australia, the Alzheimer’s drug hit another roadblock in the U.K., which found the drug ...

Today, Benzinga 's options scanner spotted 32 uncommon options trades for Biogen. This isn't normal. The overall sentiment of these big-money traders is split between 37% bullish and 31%, bearish. Out ...

For Biogen, acquiring international commercial rights to the Stoke drug bolsters its rare disease and neurology pipeline, and provides another product that could help it return to growth in the ...

Through a new deal, Biogen has bought access to a potentially first-of-its-kind drug that some doctors and analysts see as a promising treatment for a rare form of epilepsy. Biogen on Tuesday ...

NICE has upheld its decision not to recommend Alzheimer's treatments donanemab and lecanemab for NHS use, citing high costs ...

Biogen's Q4 2024 earnings showed slight revenue growth but Wall Street remains unimpressed due to weak guidance and declining key drug franchises. Leqembi's commercial performance is disappointing ...

Leqembi’s application now moves forward to the European Commission, which will issue a formal verdict for the injection that ...

The drug targets the removal of amyloids, which are plaque buildup in the brain and a key hallmark of the disease. Biogen also has a biosimilars segment producing generic drugs with a 4% YoY revenue ...

Biogen (BIIB) announced the initiation of dosing in the global clinical study, TRANSCEND. The Phase 3 study will evaluate the efficacy and ...